Pharming Group N.V. (PHAR)
NASDAQ: PHAR · Real-Time Price · USD
17.34
+0.01 (0.06%)
At close: Apr 17, 2026, 4:00 PM EDT
17.65
+0.31 (1.79%)
After-hours: Apr 17, 2026, 7:23 PM EDT
Pharming Group Employees
Pharming Group had 407 employees as of December 31, 2025. The number of employees increased by 3 or 0.74% compared to the previous year.
Employees
407
Change (1Y)
3
Growth (1Y)
0.74%
Revenue / Employee
$924,162
Profits / Employee
$7,005
Market Cap
1.24B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 407 | 3 | 0.74% |
| Dec 31, 2024 | 404 | 22 | 5.76% |
| Dec 31, 2023 | 382 | 50 | 15.06% |
| Dec 31, 2022 | 332 | 55 | 19.86% |
| Dec 31, 2021 | 277 | 15 | 5.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AbCellera Biologics | 562 |
| EyePoint | 214 |
| Zenas BioPharma | 167 |
| MapLight Therapeutics | 133 |
| MoonLake Immunotherapeutics | 130 |
| Septerna | 130 |
| DBV Technologies | 117 |
| Inhibrx Biosciences | 110 |
PHAR News
- 3 days ago - Pharming Group announces the 2026 Annual General Meeting of Shareholders - GlobeNewsWire
- 12 days ago - Pharming Group to participate in April investor conferences - GlobeNewsWire
- 17 days ago - Pharming Group announces the filing of its 2025 Annual Report and Form 20-F - GlobeNewsWire
- 23 days ago - Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older - GlobeNewsWire
- 26 days ago - Pharming Group's Leniolisib Gets Japan Approval To Treat APDS Patients Aged 4 Years And Older - Nasdaq
- 26 days ago - Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older - GlobeNewsWire
- 5 weeks ago - Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow - GlobeNewsWire
- 6 weeks ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR - GlobeNewsWire